

Symptoms, Negative Tests, and Periodicity in Parasitic Infections

©Copyright 1999 by Dr. Omar M. Amin, MD, USA

Parasitological investigations of large patient populations are rarely conducted in the United States where the illusion of freedom from parasitic infections still predominate. Such investigations are considerably more common in most third world countries where endemic parasitosis are more readily documented.

Single and concurrent infections of 5 species of protozoans have been diagnosed in 378 symptomatic and asymptomatic patients from 644 samples examined in the summer of 1996 at the Diagnostic and Educational Laboratory (DEL) of the Phoenix based Institute of Parasitic Diseases (IPD) using a concentration-sedimentation technique (Amin, 1997). Fifty-four (8.4%) were infected with *Blastocystis hominis*, 13 (2.0%) with *Cyclospora cayetanensis*, 50 (7.8%) with *Entamoeba coli*, 53 (8.2%) with *E. hartmanni*, 99 (15.4%) with *E. histolytica/E. dispar*, 28 (4.3%) with *Entamoeba spp.*, 9 (1.4%) with *E. coli* and *E. hartmanni*, 53 (8.2%) with *B. hominis* and *Entamoeba spp.*, and 17 (2.6%) with other combinations of protozoan species. More females were represented in the infected, especially the multiply infected, patients than in the uninfected. The patient population varied between 0 and 78 years of age. Very young children were not multiply infected and only adults were infected with *C. cayetanensis*. All single and multiple infections were represented in symptomatic and asymptomatic patients. (Table 1)

Enteric and extra-intestinal symptoms were associated with presumably "harmless commensals" like *E. coli* and *E. hartmanni*. Symptomatic patients infected with *E. histolytica/E. dispar* markedly outnumbered those without symptoms.

It is clear from Table 1 that a number of patients had sub-clinical infections and showed no overt intestinal or extra-intestinal symptoms. These patients have been treated and their overall health improved after having been tested, and their parasites identified, at DEL-IPD.

Table 1. Prevalence of protozoan infections in stool samples of 644 symptomatic and asymptomatic patients examined during the summer of 1996 at DEL-IPD.

CATEGORIES	NO. TESTED (%) PATIENTS WITH SYMPTOMS	NO. TESTED (%) PATIENTS WITHOUT SYMPTOMS
Single infections	233 (43.8%)	38 (33.9%)
<i>Blastocystis hominis</i>	44 (8.3%)	10 (8.9%)
<i>Cyclospora cayetanensis</i>	10 (1.9%)	3 (2.7%)
<i>Entamoeba coli</i>	47 (8.8%)	3 (2.7%)
<i>E. hartmanni</i>	44 (8.3%)	9 (8.0%)
<i>E. histolytica</i>	88 (16.5%)	11 (9.8%)
Multiple infections (above)	95 (17.8%)	12 (10.7%)
Other combinations	14 (2.6%)	3 (2.7%)
Total infected	328 (61.6%)	50 (44.6%)
Not infected	204 (38.4%)	62 (55.4%)
Total examined	532 (100%)	112 (100%)

The most common intestinal symptoms include bloating, diarrhea, flatulence, cramps, constipation, maldigestion, and malabsorption. Less frequently a patient may experience bleeding, irritable bowel, ulcerative colitis, leaky gut, and excess mucus secretion. Extra-intestinal symptoms often include fatigue, allergies, nausea, nervous/sensory disorders (memory loss, brain fog, irritability, poor coordination), skin disorders, pain, and muscle problems. Less frequent extra-intestinal symptoms may include fever, headache, immune deficiency, insomnia, weight changes, respiratory and hepatic symptoms, and peritonitis.

It is also clear from Table 1 that a number of symptomatic patients had no parasites that were detectable from fecal samples provided. These cases are probably related to one or both of the following reasons:

1. Other pathogenic organisms, ex., pathogenic bacteria, can cause symptoms comparable to those produced by


typical parasites. These may include enterotoxigenic *Escherichia coli*, Salmonella, Shigella and/or Campylobacter among others; see Paredes et al. (1996). Like the typical parasites, these bacterial parasites are also amenable to treatment with herbal products.

2. Because of the heterogeneous distribution and the cyclic nature of some of the most common human parasites, infections may not be detected in fecal samples if collected when parasites are not running in the main fecal flow; e.g., intervals of many days may intervene between amoebic "runs" which may make the microscopic examination of many stool specimens necessary to confirm a positive *Entamoeba histolytica* infection (Amin, 1994-95; Hiatt et al., 1995; Kelsall and Ravdin, 1994). The same kind of periodicity and/or adherence to the intestinal lining are also known to occur in *Giardia lamblia* (see Amin, 1994-95, Walterspiel and Pickering,

1994) and *Cyclospora cayetanensis* (see Amin, 1998). This explains the intermittent shedding and cyclic recovery of these parasites in fecal samples collected for testing. It is important to test for cyclic parasites when they are "running." The DEL-IPD kit is designed to collect 2 separate fecal samples on 2 different days to maximize parasite recovery rate. On some occasions, however, testing may have to be repeated. ♦

ABOUT THE AUTHOR

Dr. Omar M. Amin, Ph. D. is a professor of Parasitology at Arizona State University, Tempe, Arizona and the Director of the Institute of Parasitic Diseases (IPD) and its Diagnostic and Educational Laboratory (DEL), Phoenix, Arizona. He is a recognized authority in the field of Parasitology with over 100 major scientific articles and books to his credit.



REFERENCES

1. Amin, O. M. 1994-95. Relationships in parasitology: Parts I, II. Explore! for the Professional 5(5-6): 5-8, 6(1): 19-22.
2. Amin, O. M. 1997. Prevalence and host relationships of intestinal protozoan infections during the summer of 1996. Explore! for the Professional 8(2): 29-35.
3. Amin, O. M. 1998. Seasonal prevalence and host relationships of *Cyclospora cayetanensis* in North America during 1996. Parasitology International 47:53-58.
4. Hiatt, R. A., E. K. Markell, and E. NG. 1995. How many stool examinations are necessary to detect pathogenic intestinal protozoa? American Journal of Tropical Medicine and Hygiene 53:36-39.
5. Kelsall, B. L. and J. I. Ravdin. 1994. Amebiasis: Human infection with *Entamoeba histolytica*. In progress in Parasitology (Sun, T. Ed.) pp 27-54. CRC Press, Ann Arbor.
6. Paredes, P., S. Campbell-Forrester, H. L. DuPont, D. V. Ashley, J. J. Mathewson, S. Thompson, and R. Steffen. 1996. The etiology of travelers diarrhea on a Caribbean Island. Abstract no. 74, 45th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, Maryland, (December 1-5).
7. Walterspiel, J. N. and L. K. Pickering. 1994. Giardiasis and giardiasis. In Progress in Parasitology (Sun, T. ed.) pp 1-26, CRC Press, Ann Arbor.

Write Dr. Omar Amin in care of Explore Publications. Here you may also obtain his 60 pg. research from Vol. 8, #6, **Explore!**, free one time to current subscribers or \$14.00 for others. Telephone 360-424-6025, or Fax 360-424-6029.

EXPLORE! VOLUME 9, NUMBER 1, 1999

PECTASOL® MODIFIED CITRUS PECTIN

The Heroic Orange

Citrus fruits have been heroes of health for years because of vitamin C.

PECTASOL® MODIFIED CITRUS PECTIN:

A NEW HEALTH HERO

PECTASOL® MODIFIED CITRUS PECTIN is a trademarked product that utilizes a special manufacturing process to enhance absorption and utilization of crucial polysaccharide compounds.


INHIBITION OF TUMOR GROWTH

Modified citrus pectin has been reported to inhibit metastasis in published literature by key researchers.

1995 STUDY CONCLUSION:

"...oral intake of modified citrus pectin acts as a potent inhibitor of spontaneous prostate carcinoma metastasis..."

— Research study results available upon request.



EASY TO USE

PECTASOL® Modified Citrus Pectin is a natural, highly soluble pectin that can be mixed with water, juices, or blended with drinks and food.

THERE IS A DIFFERENCE

What makes PECTASOL® clearly superior to other brands of modified citrus pectin is a highly specialized and carefully controlled process that ensures the highest specifications available. Pectasol is the only brand used by leading researchers for clinical testing. There truly is a difference.

ECONUGENICS®
Protecting the Immune System

3060 KERNER BLVD., STE 5, SAN RAFAEL, CA 94901
1-800-308-5518 FAX 415-451-6277
OR CALL KLABIN MKTG. 1-800-933-9440
WWW.ECONUGENICS.COM

ECOGEN 851® FERMENTED SOY DRINK

The Prolific Soybean

Soy has been a staple food for centuries.

ECOGEN 851® IS A FERMENTED SOY DRINK

developed after ten years of culturing and selecting specific varieties of soybean. Fermentation transforms complex carbohydrates into simple sugars, proteins into amino acids, and the isoflavones into their free "active" form for optimal absorption. This adds up to optimal nutrition for those interested in maximum health.

POTENCY

97% of the isoflavones in Ecogen 851® are present in their "free form" for ready absorption.

CRUCIAL IMMUNE ENHANCING COMPONENTS

Protease inhibitors and phytates found in soybeans are present in Ecogen 851® in optimal levels. This drink combines the nutritional strengths of soy proteins with the concentrated phytochemicals and nutrients needed for health enhancement.



TRUE INTEGRATIVE HEALTH CARE

Ecogen 851® has been extensively tested as a powerful nutritional substance for people undergoing or who have completed advanced medical procedures or those rebuilding their health. Ecogen 851® is currently undergoing clinical trials by a leading West Coast prostate cancer oncologist. Pilot clinical trials were completed in 1997. Research study results available upon request.

ECONUGENICS®
Protecting the Immune System

3060 KERNER BLVD., STE 5, SAN RAFAEL, CA 94901
1-800-308-5518 FAX 415-451-6277
OR CALL KLABIN MKTG. 1-800-933-9440
WWW.ECONUGENICS.COM

OTHER IMMUNE UMBRELLA PRODUCTS FROM econUGENICS: Women's Longevity Formulas™ 1, 2 & 3 and Integrative Breast Care™, Pectagen® Formulation, Ecogen® Soybean Isoflavone Concentrate, econUGENICS Pure Bovine Cartilage, Mycoceutics® Ten Mushroom Combination, Men's Longevity® Potency Enhancement (Vitalizer), TLC-Thymic Longevity Compound™